Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.
SwerdlowSH, CampoE, HarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.
SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.
)| false
RyanRJ, AkinC, CastellsM. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol2013;26:533–543.
RyanRJAkinCCastellsM. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol2013;26:533–543.
)| false
Sanchez-MunozL, MorgadoJM, Alvarez-TwoseI. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol2016;172:56–63.
Sanchez-MunozLMorgadoJMAlvarez-TwoseI. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol2016;172:56–63.
)| false
NagataH, WorobecAS, OhCK. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A1995;92:10560–10564.
NagataHWorobecASOhCK. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A1995;92:10560–10564.
)| false
HartmannK, EscribanoL, GrattanC. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol2016;137:35–45.
HartmannKEscribanoLGrattanC. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol2016;137:35–45.
)| false
EscribanoL, Alvarez-TwoseI, Sanchez-MunozL. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol2009;124:514–521.
EscribanoLAlvarez-TwoseISanchez-MunozL. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol2009;124:514–521.
)| false
PardananiA, LimKH, LashoTL. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood2010;115:150–151.
PardananiALimKHLashoTL. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood2010;115:150–151.
)| false
AkinC, ScottLM, KocabasCN. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood2007;110:2331–2333.
AkinCScottLMKocabasCN. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood2007;110:2331–2333.
)| false
PardananiA, ChenD, AbdelrahmanRA. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia2013;27:2091–2094.
PardananiAChenDAbdelrahmanRA. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia2013;27:2091–2094.
)| false
BrockowK, JoferC, BehrendtH, RingJ. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy2008;63:226–232.
BrockowKJoferCBehrendtHRingJ. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy2008;63:226–232.
)| false
van AnrooijB, Kluin-NelemansJC, SafyM. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy2016;71:1585–1593.
van AnrooijBKluin-NelemansJCSafyM. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy2016;71:1585–1593.
)| false
GulenT, HagglundH, DahlenB, NilssonG. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med2016;279:211–228.
GulenTHagglundHDahlenBNilssonG. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med2016;279:211–228.
)| false
ZanottiR, BonadonnaP, BonifacioM. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica2011;96:482–484.
ZanottiRBonadonnaPBonifacioM. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica2011;96:482–484.
)| false
PardananiA, LimKH, LashoTL. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood2009;114:3769–3772.
PardananiALimKHLashoTL. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood2009;114:3769–3772.
)| false
WangSA, HutchinsonL, TangG. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol2013;88:219–224.
WangSAHutchinsonLTangG. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol2013;88:219–224.
)| false
ValentP, SotlarK, SperrWR. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol2014;25:1691–1700.
ValentPSotlarKSperrWR. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol2014;25:1691–1700.
)| false
ValentP, BergerJ, Cerny-ReitererS. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol2015;94:223–231.
ValentPBergerJCerny-ReitererS. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol2015;94:223–231.
)| false
JawharM, SchwaabJ, MeggendorferM. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica2017;102:1035–1043.
JawharMSchwaabJMeggendorferM. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica2017;102:1035–1043.
)| false
SperrWR, JordanJH, FieglM. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol2002;128:136–141.
SperrWRJordanJHFieglM. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol2002;128:136–141.
)| false
SchwartzLB, MetcalfeDD, MillerJS. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med1987;316:1622–1626.
SchwartzLBMetcalfeDDMillerJS. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med1987;316:1622–1626.
)| false
HornyHP, SotlarK, ValentP. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology2010;77:169–180.
HornyHPSotlarKValentP. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology2010;77:169–180.
)| false
ButterfieldJH, LiCY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?Am J Clin Pathol2004;121:264–267.
ButterfieldJHLiCY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?Am J Clin Pathol2004;121:264–267.
)| false
Sanchez-MunozL, Alvarez-TwoseI, Garcia-MonteroAC. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol2011;24:1157–1168.
Sanchez-MunozLAlvarez-TwoseIGarcia-MonteroAC. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol2011;24:1157–1168.
)| false
ReichardKK, ChenD, PardananiA. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol2015;144:493–502.
ReichardKKChenDPardananiA. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol2015;144:493–502.
)| false
JordanJH, WalchshoferS, JureckaW. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol2001;32:545–552.
JordanJHWalchshoferSJureckaW. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol2001;32:545–552.
)| false
HornyHP, SotlarK, ValentP. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am2014;34:315–321.
HornyHPSotlarKValentP. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am2014;34:315–321.
)| false
TeodosioC, MayadoA, Sanchez-MunozL. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol2015;97:49–59.
TeodosioCMayadoASanchez-MunozL. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol2015;97:49–59.
)| false
EscribanoL, Diaz AgustinB, BravoP. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma1999;35:227–235.
EscribanoLDiaz AgustinBBravoP. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma1999;35:227–235.
)| false
SotlarK, HornyHP, SimonitschI. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol2004;28:1319–1325.
SotlarKHornyHPSimonitschI. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol2004;28:1319–1325.
)| false
PardananiA, KimlingerT, ReederT. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res2004;28:777–783.
PardananiAKimlingerTReederT. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res2004;28:777–783.
)| false
MorgadoJM, Sanchez-MunozL, TeodosioCG. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod Pathol2012;25:516–521.
MorgadoJMSanchez-MunozLTeodosioCG. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod Pathol2012;25:516–521.
)| false
ChisholmKM, MerkerJD, GotlibJR. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol2015;143:527–534.
ChisholmKMMerkerJDGotlibJR. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol2015;143:527–534.
)| false
SotlarK, Cerny-ReitererS, Petat-DutterK. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol2011;24:585–595.
SotlarKCerny-ReitererSPetat-DutterK. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol2011;24:585–595.
)| false
ValentP, SotlarK, HornyHP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma2011;52:740–744.
ValentPSotlarKHornyHP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma2011;52:740–744.
)| false
MorgadoJM, PerbelliniO, JohnsonRC. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology2013;63:780–787.
MorgadoJMPerbelliniOJohnsonRC. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology2013;63:780–787.
)| false
Russano de Paiva SilvaG, TournierE, SarianLO. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore)2018;97:e10642.
Russano de Paiva SilvaGTournierESarianLO. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore)2018;97:e10642.
)| false
MayadoA, TeodosioC, Dasilva-FreireN. Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: potential role in disease dissemination. Allergy2018;73:1294–1304.
MayadoATeodosioCDasilva-FreireN. Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: potential role in disease dissemination. Allergy2018;73:1294–1304.
)| false
EscribanoL, Garcia MonteroAC, NunezR. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am2006;26:535–547.
EscribanoLGarcia MonteroACNunezR. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am2006;26:535–547.
)| false
Sanchez-MunozL, TeodosioC, MorgadoJM. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Immunol Allergy Clin North Am2014;34:297–313.
Sanchez-MunozLTeodosioCMorgadoJM. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Immunol Allergy Clin North Am2014;34:297–313.
)| false
LongleyBJ, TyrrellL, LuSZ. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet1996;12:312–314.
LongleyBJTyrrellLLuSZ. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet1996;12:312–314.
)| false
Garcia-MonteroAC, Jara-AcevedoM, TeodosioC. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood2006;108:2366–2372.
Garcia-MonteroACJara-AcevedoMTeodosioC. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood2006;108:2366–2372.
)| false
JawharM, SchwaabJ, HausmannD. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia2016;30:2342–2350.
JawharMSchwaabJHausmannD. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia2016;30:2342–2350.
)| false
JawharM, SchwaabJ, SchnittgerS. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia2016;30:136–143.
JawharMSchwaabJSchnittgerS. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia2016;30:136–143.
)| false
PardananiAD, LashoTL, FinkeC. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol2016;175:534–536.
PardananiADLashoTLFinkeC. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol2016;175:534–536.
)| false
PardananiA, LashoT, ElalaY. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol2016;91:888–893.
PardananiALashoTElalaY. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol2016;91:888–893.
)| false
PardananiA, KetterlingRP, BrockmanSR. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood2003;102:3093–3096.
PardananiAKetterlingRPBrockmanSR. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood2003;102:3093–3096.
)| false
PardananiA, BrockmanSR, PaternosterSF. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood2004;104:3038–3045.
PardananiABrockmanSRPaternosterSF. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood2004;104:3038–3045.
)| false
ArockM, SotlarK, AkinC. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia2015;29:1223–1232.
ArockMSotlarKAkinC. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia2015;29:1223–1232.
)| false
KristensenT, VestergaardH, MollerMB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn2011;13:180–188.
KristensenTVestergaardHMollerMB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn2011;13:180–188.
)| false
KristensenT, VestergaardH, Bindslev-JensenC. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol2014;89:493–498.
KristensenTVestergaardHBindslev-JensenC. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol2014;89:493–498.
)| false
Jara-AcevedoM, TeodosioC, Sanchez-MunozL. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol2015;28:1138–1149.
Jara-AcevedoMTeodosioCSanchez-MunozL. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol2015;28:1138–1149.
)| false
KristensenT, VestergaardH, Bindslev-JensenC. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy2017;72:1737–1743.
KristensenTVestergaardHBindslev-JensenC. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy2017;72:1737–1743.
)| false
SotlarK, EscribanoL, LandtO. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol2003;162:737–746.
SotlarKEscribanoLLandtO. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol2003;162:737–746.
)| false
GotlibJ, PardananiA, AkinC. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood2013;121:2393–2401.
GotlibJPardananiAAkinC. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood2013;121:2393–2401.
)| false
RossiniM, ZanottiR, BonadonnaP. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone2011;49:880–885.
RossiniMZanottiRBonadonnaP. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone2011;49:880–885.
)| false
van der VeerE, van der GootW, de MonchyJG. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy2012;67:431–438.
van der VeerEvan der GootWde MonchyJG. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy2012;67:431–438.
)| false
MetcalfeDD, PawankarR, AckermanSJ. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J2016;9:7.
MetcalfeDDPawankarRAckermanSJ. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J2016;9:7.
)| false
MorrowJD, GuzzoC, LazarusG. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol1995;104:937–940.
MorrowJDGuzzoCLazarusG. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol1995;104:937–940.
)| false
OranjeAP, MulderPG, HeideR. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol2002;27:502–506.
OranjeAPMulderPGHeideR. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol2002;27:502–506.
)| false
van DoormaalJJ, van der VeerE, van Voorst VaderPC. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy2012;67:683–690.
van DoormaalJJvan der VeerEvan Voorst VaderPC. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy2012;67:683–690.
)| false
DivekarR, ButterfieldJ. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy2015;70:1230–1238.
DivekarRButterfieldJ. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy2015;70:1230–1238.
)| false
ChoC, NguyenA, BryantKJ. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immun Inflamm Dis2016;4:64–69.
ChoCNguyenABryantKJ. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immun Inflamm Dis2016;4:64–69.
)| false
TurnerPJ, KempAS, RogersM, MehrS. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol2012;29:222–223.
TurnerPJKempASRogersMMehrS. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol2012;29:222–223.
)| false
Gonzalez de OlanoD, de la Hoz CaballerB, Nunez LopezR. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy2007;37:1547–1555.
Gonzalez de OlanoDde la Hoz CaballerBNunez LopezR. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy2007;37:1547–1555.
)| false
GulenT, HagglundH, DahlenB, NilssonG. High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience. Clin Exp Allergy2014;44:121–129.
GulenTHagglundHDahlenBNilssonG. High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience. Clin Exp Allergy2014;44:121–129.
)| false
Alvarez-TwoseI, ZanottiR, Gonzalez-de-OlanoD. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol2014;133:520–528.
Alvarez-TwoseIZanottiRGonzalez-de-OlanoD. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol2014;133:520–528.
)| false
NiedoszytkoM, BonadonnaP, Oude ElberinkJN, GoldenDB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am2014;34:365–381.
NiedoszytkoMBonadonnaPOude ElberinkJNGoldenDB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am2014;34:365–381.
)| false
Jimenez-RodriguezTW, Garcia-NeuerM, AlenazyLA, CastellsM. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy2018;11:121–142.
Jimenez-RodriguezTWGarcia-NeuerMAlenazyLACastellsM. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy2018;11:121–142.
)| false
ValentP. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy2014;44:914–920.
ValentP. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy2014;44:914–920.
)| false
van AnrooijB, van der VeerE, de MonchyJG. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol2013;132:125–130.
van AnrooijBvan der VeerEde MonchyJG. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol2013;132:125–130.
)| false
HaeberliG, BronnimannM, HunzikerT, MullerU. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy2003;33:1216–1220.
HaeberliGBronnimannMHunzikerTMullerU. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy2003;33:1216–1220.
)| false
RueffF, PrzybillaB, BiloMB. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol2009;124:1047–1054.
RueffFPrzybillaBBiloMB. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol2009;124:1047–1054.
)| false
Alvarez-TwoseI, BonadonnaP, MatitoA. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol2013;131:614–615.
Alvarez-TwoseIBonadonnaPMatitoA. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol2013;131:614–615.
)| false
CastellsMC, HornickJL, AkinC. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?J Allergy Clin Immunol Pract2015;3:350–355.
CastellsMCHornickJLAkinC. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?J Allergy Clin Immunol Pract2015;3:350–355.
)| false
Gonzalez de OlanoD, Alvarez-TwoseI, Esteban-LopezMI. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol2008;121:519–526.
Gonzalez de OlanoDAlvarez-TwoseIEsteban-LopezMI. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol2008;121:519–526.
)| false
VerburgM, OldhoffJM, KlemansRJ. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol2015;47:192–196.
VerburgMOldhoffJMKlemansRJ. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol2015;47:192–196.
)| false
RueffF, WenderothA, PrzybillaB. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol2001;108:1027–1032.
RueffFWenderothAPrzybillaB. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol2001;108:1027–1032.
)| false
CarterMC, RobynJA, BresslerPB. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol2007;119:1550–1551.
CarterMCRobynJABresslerPB. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol2007;119:1550–1551.
)| false
MarshallA, KavanaghRT, CrispAJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol1997;36:393–396.
MarshallAKavanaghRTCrispAJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol1997;36:393–396.
)| false
LehmannT, BeyelerC, LammleB. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol1996;35:898–900.
LehmannTBeyelerCLammleB. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol1996;35:898–900.
)| false
LarocheM, LivideanuC, PaulC, CantagrelA. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med2011;124:776–778.
LarocheMLivideanuCPaulCCantagrelA. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med2011;124:776–778.
)| false
DeAngeloDJ, GeorgeTI, LinderA. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia2018;32:470–478.
DeAngeloDJGeorgeTILinderA. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia2018;32:470–478.
)| false
JawharM, SchwaabJ, NaumannN. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood2017;130:137–145.
JawharMSchwaabJNaumannN. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood2017;130:137–145.
)| false
LimKH, PardananiA, ButterfieldJH. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol2009;84:790–794.
LimKHPardananiAButterfieldJH. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol2009;84:790–794.
)| false
CasassusP, Caillat-VigneronN, MartinA. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol2002;119:1090–1097.
CasassusPCaillat-VigneronNMartinA. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol2002;119:1090–1097.
)| false
HauswirthAW, Simonitsch-KluppI, UffmannM. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res2004;28:249–257.
HauswirthAWSimonitsch-KluppIUffmannM. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res2004;28:249–257.
)| false
SimonJ, LortholaryO, Caillat-VigneronN. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris)2004;52:294–299.
SimonJLortholaryOCaillat-VigneronN. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris)2004;52:294–299.
)| false
FrostMJ, FerraoPT, HughesTP, AshmanLK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther2002;1:1115–1124.
FrostMJFerraoPTHughesTPAshmanLK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther2002;1:1115–1124.
)| false
AkinC, BrockowK, D'AmbrosioC. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol2003;31:686–692.
AkinCBrockowKD'AmbrosioC. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol2003;31:686–692.
)| false
AkinC, FumoG, YavuzAS. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood2004;103:3222–3225.
AkinCFumoGYavuzAS. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood2004;103:3222–3225.
)| false
ZhangLY, SmithML, SchultheisB. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res2006;30:373–378.
ZhangLYSmithMLSchultheisB. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res2006;30:373–378.
)| false
HeinrichMC, JoensuuH, DemetriGD. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res2008;14:2717–2725.
HeinrichMCJoensuuHDemetriGD. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res2008;14:2717–2725.
)| false
MitalA, PiskorzA, LewandowskiK. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol2011;86:531–535.
MitalAPiskorzALewandowskiK. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol2011;86:531–535.
)| false
Alvarez-TwoseI, MatitoA, MorgadoJM. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget2017;8:68950–68963.
Alvarez-TwoseIMatitoAMorgadoJM. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget2017;8:68950–68963.
)| false
PrzepiorkaD, GiraltS, KhouriI. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol1998;57:24–28.
PrzepiorkaDGiraltSKhouriI. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol1998;57:24–28.
)| false
NakamuraR, ChakrabartiS, AkinC. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant2006;37:353–358.
NakamuraRChakrabartiSAkinC. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant2006;37:353–358.
)| false
ValentP, AkinC, SperrWR. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res2003;27:635–641.
ValentPAkinCSperrWR. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res2003;27:635–641.
)| false
MatitoA, MorgadoJM, Alvarez-TwoseI. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One2013;8:e76116.
MatitoAMorgadoJMAlvarez-TwoseI. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One2013;8:e76116.
)| false
ErbenP, SchwaabJ, MetzgerothG. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol2014;93:81–88.
ErbenPSchwaabJMetzgerothG. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol2014;93:81–88.
)| false
HoermannG, GleixnerKV, DinuGE. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy2014;69:810–813.
HoermannGGleixnerKVDinuGE. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy2014;69:810–813.
)| false
PardananiA. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood2013;121:3085–3094.
PardananiA. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood2013;121:3085–3094.
)| false
HermansMAW, ArendsNJT, Gerth van WijkR. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol2017;119:304–309.
HermansMAWArendsNJTGerth van WijkR. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol2017;119:304–309.
)| false
MatitoA, MorgadoJM, Sanchez-LopezP. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol2015;167:47–56.
MatitoAMorgadoJMSanchez-LopezP. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol2015;167:47–56.
)| false
GuyerAC, SaffRR, ConroyM. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract2015;3:94–100.
GuyerACSaffRRConroyM. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract2015;3:94–100.
)| false
WoidackiK, ZenclussenAC, SiebenhaarF. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?Front Immunol2014;5:231.
WoidackiKZenclussenACSiebenhaarF. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?Front Immunol2014;5:231.
)| false
CiachK, NiedoszytkoM, Abacjew-ChmylkoA. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). PLoS One2016;11:e0146924.
CiachKNiedoszytkoMAbacjew-ChmylkoA. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). PLoS One2016;11:e0146924.
)| false
MatitoA, Alvarez-TwoseI, MorgadoJM. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol2011;156:104–111.
MatitoAAlvarez-TwoseIMorgadoJM. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol2011;156:104–111.
)| false
UlbrichF, EngelstadterH, WittauN, SteinmannD. Anaesthetic management of emergency caesarean section in a parturient with systemic mastocytosis. Int J Obstet Anesth2013;22:243–246.
UlbrichFEngelstadterHWittauNSteinmannD. Anaesthetic management of emergency caesarean section in a parturient with systemic mastocytosis. Int J Obstet Anesth2013;22:243–246.
)| false
